BACKGROUND Influences of atorvastatin on atherosclerosis and glycemic metabolism may be related to its potential impact on circulating adiponectin, an adipocyte that exerts anti-inflammatory, ant-atherosclerotic, and anti-oxidative effects. However, results of previous randomized controlled trials (RCTs) were not consistent. We performed a meta-analysis of RCTs to systematic evaluate the influence of atorvastatin on circulating adiponectin. METHODS Relevant studies were identified via search of electronic databases of PubMed, Embase, and Cochrane's Library. A random-effect model was applied to pool the results via incorporating the potential heterogeneity. Predefined meta-regression and subgroup analyses were used to evaluate the influences of study characteristics on the outcome. RESULTS Fourteen datasets from ten RCTs including 931 patients were included. Pooled results showed that atorvastatin did not significantly affect circulating adiponectin as compared with controls (weighed mean difference = - 0.27 μg/mL, 95% confidence interval: - 0.89 to 0.35 μg/mL, p = 0.39). Results of univariate meta-regression analyses showed that study characteristics including number of patients, mean age, proportion of male patients, body mass index, dose of atorvastatin, or treatment duration did not significantly affect the outcome (p all > 0.05). Moreover, subgroup analyses showed that atorvastatin did not significantly affect circulating adiponectin in studies stratified according to these study characteristics (p all > 0.05). CONCLUSIONS Atorvastatin treatment does not significantly affect circulating adiponectin. Influences of atorvastatin on atherosclerosis and glycemic metabolism are not likely to be mediated by modulation of circulating adiponectin.

中文翻译：

---

阿托伐他汀治疗对循环脂联素的影响：一项随机对照试验的荟萃分析。

背景技术阿托伐他汀对动脉粥样硬化和血糖代谢的影响可能与其对循环脂联素（发挥抗炎，抗动脉粥样硬化和抗氧化作用的脂肪细胞）的潜在影响有关。但是，先前的随机对照试验（RCT）的结果不一致。我们进行了RCT的荟萃分析，以系统评估阿托伐他汀对循环脂联素的影响。方法通过检索PubMed，Embase和Cochrane图书馆的电子数据库，确定了相关研究。应用了随机效应模型，通过合并潜在的异质性来汇总结果。预定义的元回归和亚组分析用于评估研究特征对结果的影响。结果包括十个RCT的十四个数据集，包括931名患者。汇总结果显示，与对照组相比，阿托伐他汀对循环脂联素没有明显影响（加权平均差异=-0.27μg/ mL，95％置信区间：-0.89至0.35μg/ mL，p = 0.39）。单变量荟萃回归分析的结果表明，包括患者人数，平均年龄，男性患者比例，体重指数，阿托伐他汀剂量或治疗持续时间在内的研究特征对结局均无显着影响（p> 0.05）。此外，亚组分析显示，在根据这些研究特征进行分层的研究中，阿托伐他汀对循环脂联素没有明显影响（p> 0.05）。结论阿托伐他汀治疗不会显着影响循环脂联素。